1 BTC
=
- USD
Madrigal Pharmaceuticals, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Madrigal Pharmaceuticals, Inc. Common Stock
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Market Statistics
Trading Metrics
How to Buy MDGL
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy MDGL
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesMadrigal Pharmaceuticals announced it will release Q1 2026 financial results on May 6, 2026, followed by a live webcast at 8 a.m. ET. The company is a biopharmaceutical firm focused on MASH treatment, with its FDA and European Commission-approved medication Rezdiffra (resmetirom) for moderate to advanced fibrosis cases, and an ongoing Phase 3 trial for cirrhosis treatment.
The regenerative medicine market, projected to reach $578 billion by 2033, faces a critical manufacturing challenge in scaling cell and gene therapies. Several companies are addressing this bottleneck through different approaches: Prime Medicine with prime editing technology, Madrigal Pharmaceuticals with sustained therapeutic results, Iovance Biotherapeutics with FDA-approved TIL therapy, Denali Therapeutics with protein engineering, and Avaà Bio with a Master Cell Bank for encapsulated cell products that enable off-the-shelf manufacturing.
Summit Therapeutics faces significant near-term risk as its FDA decision on ivonescimab is expected by November 14, 2026. The drug failed to demonstrate statistically significant overall survival improvement in non-Chinese patient populations, which the FDA requires for approval. Meanwhile, Axsome Therapeutics and Madrigal Pharmaceuticals are positioned to potentially outperform Summit by year-end, driven by upcoming catalysts and strong revenue growth.
RTW Investments established a new $193 million position in Apellis Pharmaceuticals by acquiring 7.67 million shares in Q4 2025. Despite a 29% stock decline over the past year, the investment signals confidence in the company's commercial-stage biotech portfolio, which generated $689 million in product revenue driven by its flagship therapy. The position represents a calculated pivot toward more durable revenue streams within a portfolio focused on high-growth biotech names.
Madrigal Pharmaceuticals announced an exclusive global licensing agreement with Suzhou Ribo Life Science for six preclinical siRNA programs to expand its MASH treatment pipeline. The deal includes a $60 million upfront payment with potential cumulative payments reaching $4.4 billion upon milestone achievement. Madrigal's pipeline now includes over 10 programs anchored by its approved drug Rezdiffra, with additional candidates including MGL-2086 (GLP-1 agonist) and Ervogastat (DGAT-2 inhibitor) in development.